Incyte (INCY) to Halt Ruxolitinib + Capecitabine Phase 3 in Advanced or Metastatic Pancreatic Cancer

February 11, 2016 6:46 AM

Incyte Corporation (Nasdaq: INCY) announced its decision to discontinue the Phase 3 study (JANUS 1) of ruxolitinib or placebo in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found